Table 1 a. Clinical characteristics at diagnosis and TCR status, b. Refractoriness to proteasome inhibitors, immunomodulatory imide drugs and monoclonal antibodies, c. First salvage treatment post triple refractory status.
a. Clinical characteristics at diagnosis and TCR statusClinical characteristics at diagnosis and TCR status | ||
|---|---|---|
Parameter | At diagnosis | At TCR disease |
Age at diagnosis, median (range) | 61.3 (31–89) | 64.6 (32–93) |
Sex, % females | 39 | – |
International staging system (ISS; n = 207) |  | c |
 Stage I | 23% |  |
 Stage II | 32% |  |
 Stage III | 45% |  |
Revised ISS (n = 177) |  | – |
 Stage I | 14% |  |
 Stage II | 56% |  |
 Stage III | 30% |  |
High-risk cytogenetics | 56% | 86% (95/110) |
 (based on mSMART 3.0 classification) | (116/208) |  |
 Specific cytogenetic features |  |  |
 t(4;14) | 19% (37/198) | 20% (21/106) |
 t(11;14) | 24% (47/199) | 24% (25/105) |
 Deletion 17p | 22% (44/199) | 38% (41/109) |
 t(14;16)/t(14;20) | 9% (17/195) | 4% (4/105) |
 1q gain | 55% (76/136) | 74% (81/110) |
 Deletion 1p | 9% (11/121) | 4% (4/103) |
b Refractoriness to proteasome inhibitors, immunomodulatory imide drugs and monoclonal antibodies | |
|---|---|
Drug class | N = 249 (%) |
Proteasome inhibitors | Â |
Bortezomib | 41 (16) |
Carfilzomib | 25 (10) |
Ixazomib | 14 (6) |
Bortezomib + carfilzomib | 103(41) |
Bortezomib + ixazomib | 17 (7) |
Carfilzomib + ixazomib | 11 (4) |
Bortezomib + carfilzomib + ixazomib | 38 (15) |
Immunomodulatory drugs | Â |
Lenalidomide | 53 (21) |
Pomalidomide | 29 (12) |
Thalidomide | 1 (0.4) |
Lenalidomide and pomalidomide | 138 (55) |
Lenalidomide, pomalidomide and thalidomide | 28 (11) |
Monoclonal antibodies | Â |
Daratumumab | 185 (74) |
Elotuzumab | 5 (2) |
Daratumumab and elotuzumab | 48 (19) |
Daratumumab and isatuximab | 4 (2) |
Daratumumab, elotuzumab and isatuximab | 7 (3) |
c First salvage treatment post triple refractory status. | ||
|---|---|---|
Drug class | N = 227 (%) | |
1. | PI + IMiD therapy (without mAb, venetoclax or bendamustine) | 57 (25) |
2. | Monoclonal antibody-based therapies (include combination with PIs, IMiDs, but not venetoclax) | 50 (22) |
CD38-based | 34 (15) | |
Elotuzumab-based | 16 (7) | |
3. | VDT-PACE like regimens | 37 (16) |
4. | PI-based therapies (without IMiD, mAbs or venetoclax) | 27 (12) |
5. | Alkylator combinations (without PI, IMiD, mAb or venetoclax) | 17 (7) |
6. | Venetoclax-based regimens (including combination with PIs, IMiDs, mAbs, bendamustine) | 11 (5) |
7. | CAR-T therapy | 7 (4) |
8. | IMiD based therapies (without PIs, mAbs or venetoclax) | 6 (3) |
9. | Bendamustine-based combinations (includes PIs, IMiDs, mAbs, no venetoclax) | 5 (2) |
10. | BCMA-directed antibodies | 4 (2) |
11. | Miscellaneousa | 6 (3) |
